See AW, Conway P, Frydenberg M, Haxhimolla H, et al. Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. Int J Cancer 2024 Jun 19. doi: 10.1002/ijc.35052.
PMID: 38898626